
Company valuation, historical trends, and peer comparisons.
According to Tarsus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.32B. This represents a change of 15.30% compared to the average of 2.88B of the last 4 quarters.
The mean historical Enterprise Value of Tarsus Pharmaceuticals, Inc. over the last ten years is 937.01M. The current 3.32B Enterprise Value has changed 254.69% with respect to the historical average. Over the past ten years (40 quarters), TARS's Enterprise Value was at its highest in in the December 2025 quarter at 3.41B. The Enterprise Value was at its lowest in in the March 2018 quarter at 0.
Average
937.01M
Median
371.99M
Minimum
85.84M
Maximum
3.33B
Discovering the peaks and valleys of Tarsus Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 414.59%
Maximum Annual Enterprise Value = 3.33B
Minimum Annual Increase = -56.44%
Minimum Annual Enterprise Value = 85.84M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 3.33B | 61.73% |
| 2024 | 2.06B | 414.59% |
| 2023 | 400.28M | 29.34% |
| 2022 | 309.47M | 5.61% |
| 2021 | 293.03M | -56.44% |
| 2020 | 672.66M | 95.71% |
| 2019 | 343.71M | 300.42% |
The current Enterprise Value of Tarsus Pharmaceuticals, Inc. (TARS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.93B
5-year avg
1.28B
10-year avg
937.01M
Tarsus Pharmaceuticals, Inc.’s Enterprise Value is greater than Sol-Gel Technologies Ltd. (196.10M), greater than Verrica Pharmaceuticals Inc. (48.16M), less than Arcutis Biotherapeutics, Inc. (4.11B), greater than Turn Therapeutics Inc. (298.90M), greater than Harrow Health, Inc. (1.28B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 196.10M | $211.99M | |
| 48.16M | $57.55M | |
| 4.11B | $4.03B | |
| 298.90M | $303.07M | |
| 1.28B | $1.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tarsus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tarsus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Tarsus Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS)?
What is the 3-year average Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS)?
What is the 5-year average Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS)?
How does the current Enterprise Value for Tarsus Pharmaceuticals, Inc. (TARS) compare to its historical average?